Saint-Germer-de-Fly (FR)
{name}
{subtitle}
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~41 mi. (Rouen, France, +159 more cities)
facility
CHU de Rouen ( Site 0493)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~41 mi. (Rouen, France, +127 more cities)
facility
Centre Henri Becquerel ( Site 1904)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~41 mi. (Rouen, France, +145 more cities)
facility
CHU de Rouen ( Site 1113)
condition
Non-Small Cell Lung Carcinoma
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~41 mi. (Rouen, France, +115 more cities)
facility
Centre Henri Becquerel ( Site 0607)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
city
~41 mi. (Rouen, France, +84 more cities)
facility
Site FR33017
biomarker
CLDN18 Expression
condition
Pancreatic Adenocarcinoma
drug
gemcitabine, +2 more drugs
drug type
chemotherapy, +1 more type
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
city
~41 mi. (Rouen, France, +70 more cities)
facility
Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0509)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~53 mi. (Amiens, France, +226 more cities)
facility
CHU Amiens Picardie Site Sud Amiens ( Site 0438)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~53 mi. (Amiens, France, +158 more cities)
facility
Clinique de l'Europe-Service de pneumologie ( Site 0816)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types